risperidone / Generic mfg. - LARVOL DELTA

PS08 Pharmacists' perceptions of the use of antipsychotics in psychodermatology. (PubMed, Br J Dermatol) - "Risperidone was identified as the antipsychotic with which respondents were most familiar...Consequently, pharmacists can fill a critical gap by providing counselling when dispensing antipsychotics for dermatological indications. Identifying this knowledge gap and potential areas for improvement fosters stronger interdisciplinary collaboration and optimizes care for patients with psychodermatological conditions."

Journal • CNS Disorders • Dermatology • Movement Disorders • Psychiatry

Second-generation antipsychotics - Cardiac ion channel modulation and QT interval disturbances: A review. (PubMed, Biomol Biomed) - "A narrative literature review was conducted using PubMed, Web of Science, and Google Scholar, without year restrictions, focusing on English-language experimental and clinical studies related to clozapine, olanzapine, risperidone, quetiapine, and ziprasidone. Notably, the observed variability in the ratio of half-maximal inhibitory concentration to maximum free plasma concentration (IC₅₀/Cmax,free) reflects its dependence on both the degree of hERG inhibition and the pharmacokinetic properties specific to each SGA. Additionally, several SGAs affect other potassium, sodium, and calcium currents, which may either mitigate or exacerbate the consequences of IKr inhibition. In conclusion, QT interval prolongation associated with SGAs is primarily driven by hERG potassium channel blockade, although the degree of this effect varies significantly among different agents. This variability highlights the necessity for electrocardiogram (ECG) monitoring and..."

Journal • Review • Cardiovascular • CNS Disorders • Psychiatry

Disproportionality and time-to-onset analyses of drug-induced weight gain using the Japanese Adverse Drug Event Report database. (PubMed, Drug Discov Ther) - "Pregabalin showed the earliest median onset at 19 days (early failure), followed by olanzapine and risperidone at 1-2 months, pioglitazone at 2 months, and clozapine at 6 months, all classified as random failure types. These findings underscore the need for careful weight monitoring during treatment, particularly early with pregabalin and long-term with clozapine and pioglitazone. Prospective studies are warranted to clarify causal relationships and clinical implications."

Adverse events • Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity

Piracetam for Risperidone-associated Hypersalivation: A Novel Treatment Approach in an Adolescent Case. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal

The nitric oxide synthase inhibitor 7-nitroindazole attenuates social withdrawal and memory impairments induced by Blockade of the NMDA receptor in the rat. (PubMed, Psychopharmacology (Berl)) - "The present results indicate that 7-NI is sensitive to glutamate blockade since it decreased behavioural impairments resembling the negative symptoms and cognitive deficits of schizophrenia. Moreover, these findings corroborate the potential of 7-NI as an adjunctive molecule for the medication of schizophrenia."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia • NOS1

Prescribing Patterns and Adverse Reactions of Antipsychotics in a North Indian Psychiatry Outpatient Department. (PubMed, Cureus) - "It is necessary to justify the antipsychotic drug prescribing pattern. By evaluating prescription habits, one may determine the incidence of pharmacovigilance and polytherapy, which helps to minimize and avoid adverse medication responses."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Movement Disorders • Psychiatry • Schizophrenia

Psychiatric Medications Procurement at Primary Health Centers (PHCs) in Tumkur: Insights from an Effectiveness Implementation Hybrid Randomized Controlled Trial on Mental Health Tele-mentoring of Primary Care Doctors (PCDs). (PubMed, Indian J Psychol Med) - "Within-group analysis over time showed a statistically significant increase in the proportion of PHCs procuring amitriptyline in both the OMHT arm (p = .01) and the TAU arm (p = .03). Additionally, in the OMHT arm, there was a significant increase over time in the proportion of PHCs procuring alprazolam (p = .03) and clonazepam (p = .02). In the between-group comparison of total quantities procured during the combined training and post-training phases, the OMHT arm demonstrated significantly higher procurement of escitalopram (p < .01) and risperidone (p < .01) compared to the TAU arm, indicating greater confidence in prescribing practices of key psychiatric medications among trained PCDs. Clinical Trials Registry of India (CTRI/2024/02/062906)."

Journal • CNS Disorders • Mental Retardation • Psychiatry

Connectional diaschisis associated with acute psychosis after right thalamic stroke: A case report. (PubMed, Cortex) - "The patient was treated with risperidone and venlafaxine, leading to an improvement in psychotic symptoms at both discharge and follow-up. Understanding these network-level disruptions may offer valuable insights into therapeutic approaches and prognostic evaluation."

Journal • Cardiovascular • CNS Disorders • Psychiatry

Effects of risperidone on amino acid metabolism, glucose, and kidney function in healthy adults: A pilot randomized controlled trial. (PubMed, PLoS One) - "Short-term risperidone affects d-serine metabolism without instigating acute adverse effects on kidney or glucose homeostasis in healthy individuals. Clinical Trial Registry number: This study was registered with the Japan Registry for Clinical Trials (jRCTs041210165)."

Clinical • Journal • Acute Kidney Injury • Nephrology • Renal Disease

Trajectory analysis of BMI increase induced by second-generation antipsychotics in first-episode schizophrenia: a secondary analysis based on CNFEST***. (PubMed, Schizophrenia (Heidelb)) - P=N/A | "After quality control, a total of 361 drug-naïve FES patients treated with olanzapine, risperidone, or aripiprazole were included. A high-risk subgroup (LBRI) with rapid early weight gain was identified, driven by olanzapine use, shorter DUP, and lower educational attainment. These findings advocate for dynamic risk stratification and early preventive interventions in vulnerable FES patients (Trial Registration: This trial was registered at ClinicalTrials.gov (Identifier: NCT01057849) on January 26, 2010)."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Shared Psychotic Disorder in the Digital Age: A Case Series of Virtual "Folie à Trois". (PubMed, Consort Psychiatr) - "This case underscores that psychological proximity fostered through immersive digital platforms may suffice for the transmission of delusional beliefs. Clinicians must routinely explore virtual relationships and digital group identities as potential vectors of psycho-pathology. Early detection, digital boundary setting, and integrative therapy approaches are essential in managing such emerging presentations."

Journal • CNS Disorders • Insomnia • Psychiatry • Sleep Disorder

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Undiagnosed Delusional Infestation Leading to Severe Self-Inflicted Injuries: A Case Report. (PubMed, Case Rep Psychiatry) - "Treatment with low-dose risperidone and doxepin was initiated following empathic, nonconfrontational engagement...This case highlights the risk of severe self-injury in DI and underscores the need for timely psychiatric evaluation and a compassionate, collaborative approach. Reframing treatment goals to prioritize symptom relief over delusional challenge may enhance engagement and facilitate recovery."

Journal • Dermatology • Pruritus • Psychiatry • Thermal Injury

Association of propranolol with treatment-emergent akathisia during aripiprazole treatment. (PubMed, Ideggyogy Sz) - "The objective of the present retrospective study was to assess the prevalence of akathisia in patients receiving propranolol or metoprolol comedication, as well as in those not receiving any CYP2D6 inhibitors such as propranolol, metoprolol, risperidone. However, two major limitations should be considered: akathisia was not assessed using a standardized clinical rating scale, and the majority of patients (80.6%) received antipsychotic combination therapy, which may have influenced the findings. Further prospective studies are needed to confirm these findings based on retrospective, naturalistic analysis about the development of aripiprazole-induced akathisia."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Comprehensive DNA methylation analysis of brain and peripheral tissues following chronic risperidone treatment in common marmosets. (PubMed, Neurosci Res) - "We also found that risperidone-treated neuroblastoma cells showed methylation patterns closely resembling those of the hippocampus, suggesting that the epigenetic changes are partly conserved in the cell models. These findings offer a framework for understanding the molecular basis of antipsychotic actions and for identifying potential epigenetic markers relevant to clinical effects."

Journal • CNS Disorders • Mental Retardation • Neuroblastoma • Oncology • Psychiatry • Schizophrenia • Solid Tumor

Low Oxygen Saturation During Risperidone Therapy: A Multispecialty Approach. (PubMed, Cureus) - "There is a paucity of literature describing low oxygen saturation without acute respiratory compromise during risperidone therapy. Therefore, we present a rare case of low oxygen saturation in a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency and variant hemoglobin (elevated HbA₂) on risperidone therapy, who exhibited no respiratory compromise."

Journal • Acute Respiratory Distress Syndrome • Bipolar Disorder • CNS Disorders • Infectious Disease • Metabolic Disorders • Mood Disorders • Pneumonia • Psychiatry • Respiratory Diseases • Schizophrenia

Antioxidant Supplementation with ProCloSupp Protects Against Renal Toxicity of Atypical Antipsychotics in Rats: Implications for Safer Treatment Strategies. (PubMed, Life (Basel)) - "Atypical antipsychotics (AAP), including clozapine (Clo), aripiprazole (Ari), and risperidone (Ris), are widely used in psychiatry but can lead to kidney damage due to oxidative stress. In conclusion, subchronic Clo, Ari, and Ris exposure induces oxidative renal damage in rats, while PCS supplementation enhances antioxidant defences and attenuates tissue damage. These results support PCS as a potential nephroprotective strategy in antipsychotic therapy."

Journal • Preclinical • CNS Disorders • Psychiatry • CAT

The Development of Risperidone-Loaded Microfibers via Centrifugal Spinning to Enhance the Palatability of a Potential Drug for Autistic Children. (PubMed, Pharmaceutics) - " Risperidone-loaded sucrose microfibers represent a promising fast-dissolving oral delivery system for children with ASD. This child-friendly formulation improves palatability and compliance while maintaining safety and drug release performance."

Journal • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Pediatrics

Review of Autism Spectrum Disorder (ASD): Epidemiology, Aetiology, Pathology, and Pharmacological Treatment. (PubMed, Pharmaceuticals (Basel)) - "Atypical antipsychotics (AAPs), particularly risperidone and aripiprazole, provide superiority over other drug classes of pharmacological interventions. These ADRs may lead to chronic diseases such as diabetes and cardiovascular conditions, adding strain to healthcare systems beyond the original treatment of ASD. This narrative review enhances our understanding of ASD and highlights a gap in current knowledge about the evaluation of the effectiveness and safety of pharmacological treatments, especially AAPs for ASD in paediatric patients."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Cardiovascular • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Pediatrics • Psychiatry

Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate. (PubMed, Autism Res) - "CBD demonstrated a better efficacy and safety profile compared to RISP in reversing ASD-like behaviors and associated neurobiological alterations in the zebrafish model. These findings suggest that CBD may offer a safer and more effective therapeutic alternative for managing ASD-related symptoms."

Journal • Autism Spectrum Disorder • Genetic Disorders • GFAP

Contrasting Effects of Clozapine and Risperidone on Cholesterol Metabolism, Synaptic Proteins, and Transcriptional Regulation in Human LUHMES Neurons. (PubMed, Mol Neurobiol) - "In contrast, risperidone upregulated TCF4, TCF7L1, FOS, HMGN1, and coactivators RREB1 and NCOA3, promoting Wnt signaling, chromatin accessibility and synaptic plasticity. Taken together, our data unveil distinct proteomic, transcriptional and epigenetic programs orchestrated by clozapine and risperidone, providing novel molecular insights into their divergent clinical actions."

Journal • CNS Disorders • HMGN1 • JUNB • NCOA3 • RREB1 • TCF4

Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine and Risperidone in Alzheimer's Disease: A Real□World Cohort Study with Treatment Effect Heterogeneity Analysis. (PubMed, medRxiv) - "Aripiprazole and quetiapine were associated with lower mortality compared to olanzapine and risperidone. Treatment effect heterogeneity suggests the need for individualized prescribing based on patient characteristics such as comorbid T2DM."

Heterogeneity • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Recruiting ➔ Completed

Trial completion • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia

Magnetic Seizure Therapy for Psychotic Disorders (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Epilepsy • Psychiatry

Vinpocetine Improves Seizure Control and Non-Seizure Outcomes in Patients with GABAA-R Loss-of-Function Variants (AES 2025) - "Improvement in OCD, anxiety and depression leading to discontinuation of risperidone in one patient... Vinpocetine add-on therapy may be considered in patient with pathogenic LoF GABAA-R variants, with evidence that this can reduce seizures, interictal epileptic discharges and behavioral disorders, as well as improving adaptive behavior and cognition."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Behavior Disorders • CNS Disorders • Depression • Epilepsy • Genetic Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Otorhinolaryngology • Psychiatry